PANTHERx® Rare Announces Exciting Leadership Changes: New President and Key Hire
June 20, 2023 PITTSBURGH – PANTHERx® Rare, the nation’s leading rare disease pharmacy, is excited to announce significant leadership changes as part of its ongoing growth and strategic development. These changes signify a new chapter in the Company’s...
Read More
PANTHERx® Rare Pharmacy Expands Services to Include Dispensing AYVAKIT® (avapritinib) for the Expanded Approval for Treatment of Indolent Systemic Mastocytosis (ISM)
June 19, 2023 PITTSBURGH – Blueprint Medicines recently announced the approval of AYVAKIT® (avapritinib) for the expanded indication of adults with Indolent Systemic Mastocytosis (ISM). AYVAKIT was previously approved for the treatment of adults with...
Read More
PANTHERx® Rare Announces Partnership with Biocodex for the Distribution of DIACOMIT® (stiripentol) for the Treatment of Seizures Associated with Dravet Syndrome in Patients 2 Years of Age and Older Taking Clobazam
June 27, 2022 PITTSBURGH – PANTHERx® Rare announces that it has been selected by Biocodex as their new exclusive U.S. pharmacy distribution partner for DIACOMIT® (stiripentol). DIACOMIT is a new molecular entity approved by the FDA in 2018 for the adjunctive...
Read More
PANTHERx Rare Celebrates Fifth Patient Choice Award Win
May 4, 2022 PITTSBURGH – For a fifth time, PANTHERx® Rare has been recognized as the winner of the annual, Specialty Pharmacy Patient Choice Award™. Since 2016, the Managed Markets Insights & Technology Zitter Health Insight’s (MMIT ZHI) Patient Choice...
Read More
PANTHERx® Rare Selected by Aadi Bioscience to Distribute FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for advanced malignant perivascular epithelioid cell neoplasm (PEComa)
February 24, 2022 PANTHERx® Rare announces that it has been selected by Aadi Bioscience as the exclusive U.S. pharmacy distribution partner for new drug FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound). FYARRO, an...
Read More
PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome
January 13, 2022 PANTHERx® Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev®...
Read More